{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T18:21:55Z","timestamp":1780510915013,"version":"3.54.1"},"reference-count":55,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3,14]]},"abstract":"<jats:p>Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are rare malignancies deriving from the endocrine system in the gastrointestinal tract including the pancreas. Prognosis is greatly heterogenous due to its dependency on various factors, most importantly stage and differentiation. Several studies report an alarming rise in incidence in the past decade. Despite there being some therapeutical options, best therapy sequence still needs to be defined, particularly for unresectable and\/or intermediate and high-grade NENs. Peptide receptor radionuclide therapy (PRRT) was approved in Europe and USA in 2017 and 2018, respectively. Studies with real-world systematic data on characteristics and treatment patterns of PRRT-receiving patients was non-existent at the time of this writing. In this retrospective study, we identified within the German NET-Registry 203 patients diagnosed with GEP-NEN having received PRRT from 1995 to 2023. We assessed general clinical patient characteristics, disease-specific characteristics, treatments and outcomes. To obtain a more up-to-date picture of treatment modalities and outcomes, a subgroup of the study population was allocated to the \u201ctherapy cohort,\u201d defined by patients with date of first diagnosis between 2010 and 2023 (open cohort). Mean age of the study population was 58 years (SD 12 years) with 51.7% being men. Most patients had a WHO performance score of 0 to 1 (41.4% and 50.5%, respectively). Most NEN cases were of small intestine\/pancreatic origin (46.3% and 45.3%, respectively) and displayed well\/moderate differentiation (55.3%). Ki-67 was generally within the 3% to 20% range (57.92%). Most patients presented with metastasis at diagnosis (73.9%). Somatostatin analogs (SSAs), chemotherapy and surgery were the most common non-PRRT therapy options (65.3%, 60.2%, and 50.0%, respectively). PRRT was most often applied as third- or second-line therapy (42.3% and 36.6%, respectively), usually after surgery and\/or SSA treatment. As PRRT had been administered using different regimens, tumor response evaluation showed mixed responses. Given the low sample size and considerable amount of missing response data, no correlation analysis between PRRT sequencing and tumor response could be performed. Overall, the clinical characteristics and treatment patterns tend to follow trends observed in other studies or medical guidelines. Finally, this study presents real-world data that more accurately describes GEP-NEN disease in Germany and treatment modalities after PRRT\u2019s approval.<\/jats:p>","DOI":"10.1097\/md.0000000000041853","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T15:03:03Z","timestamp":1742310183000},"page":"e41853","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Clinical characteristics and treatment patterns of patients with gastroenteropancreatic neuroendocrine neoplasia in Germany receiving peptide receptor radionuclide therapy: A real-world data registry-based study"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1272-5543","authenticated-orcid":false,"given":"Claus","family":"von Hessert-Vaudoncourt","sequence":"first","affiliation":[{"name":"Department of Hematology, Oncology, and Cancer Immunology (CCM), Charit\u00e9 Universitaetsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Maasberg","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Gastroenterology, Asklepios Klinik St. George, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehara","family":"Begum","sequence":"additional","affiliation":[{"name":"Department of General, Visceral, Thoracic and Endocrine Surgery, Johannes Wesling Hospital Minden, Minden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Rinke","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, University Hospital Gie\u00dfen and Marburg, Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"P\u00f6ppel","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Nuklearmedizin, Universit\u00e4tsklinikum Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bence","family":"Sipos","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University of T\u00fcbingen, T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Grohe","sequence":"additional","affiliation":[{"name":"Department of Pneumology, Evangelische Lungenklinik Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Fottner","sequence":"additional","affiliation":[{"name":"Schwerpunkt Endokrinologie und Stoffwechselerkrankungen, I. Medizinischen Klinik und Poliklinik; ENETS Center of Excellence, Universit\u00e4tsmedizin der Johannes Gutenberg-Universit\u00e4t Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Stintzing","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, and Cancer Immunology (CCM), Charit\u00e9 Universitaetsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Grabowski","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, and Cancer Immunology (CCM), Charit\u00e9 Universitaetsmedizin Berlin, Berlin, Germany"},{"name":"Interdisciplinary Oncology and Palliative Care, Hospital Gemeinschaftskrankenhaus Havelh\u00f6he, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of the German NET Registry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260108","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann Oncol"},{"key":"R2-20260108","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system.","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"key":"R3-20260108","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11912-021-01029-7","article-title":"Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences?","volume":"23","author":"Das","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"R4-20260108","doi-asserted-by":"crossref","first-page":"19949","DOI":"10.1002\/cam4.6510","article-title":"Site-specific trends in gastroenteropancreatic neuroendocrine neoplasms in Bavaria, Germany.","volume":"12","author":"Grundmann","year":"2023","journal-title":"Cancer Med"},{"key":"R5-20260108","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1093\/jnci\/djs208","article-title":"TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study.","volume":"104","author":"Rindi","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"R6-20260108","first-page":"29","article-title":"Gastroenteropancreatic neuroendocrine tumors: diagnosis and treatment.","volume":"26","author":"D\u00edez","year":"2013","journal-title":"Ann Gastroenterol"},{"key":"R7-20260108","doi-asserted-by":"crossref","first-page":"682","DOI":"10.7326\/M14-2132","article-title":"Metachronous hormonal syndromes in patients with pancreatic neuroendocrine tumors: a case-series study.","volume":"162","author":"de Mestier","year":"2015","journal-title":"Ann Intern Med"},{"key":"R8-20260108","first-page":"175","article-title":"Non-functioning neuroendocrine pancreatic tumors transforming to malignant insulinomas \u2013 four cases and review of the literature.","volume":"40","author":"Juhlin","year":"2019","journal-title":"Neuro Endocrinol Lett"},{"key":"R9-20260108","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1186\/s12885-018-5057-3","article-title":"Delays and routes to diagnosis of neuroendocrine tumours.","volume":"18","author":"Basuroy","year":"2018","journal-title":"BMC Cancer"},{"key":"R10-20260108","doi-asserted-by":"crossref","first-page":"e01147","DOI":"10.14309\/crj.0000000000001147","article-title":"Slow and steady: a slowly progressing neuroendocrine tumor.","volume":"10","author":"Zheng","year":"2023","journal-title":"ACG Case Rep J"},{"key":"R11-20260108","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1677\/ERC-08-0017","article-title":"Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours.","volume":"15","author":"Pape","year":"2008","journal-title":"Endocr Relat Cancer"},{"key":"R12-20260108","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.cgh.2008.02.052","article-title":"Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors.","volume":"6","author":"Arnold","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R13-20260108","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1080\/00365520903082432","article-title":"Small intestinal neuroendocrine tumors: prognostic factors and survival.","volume":"44","author":"Bergestuen","year":"2009","journal-title":"Scand J Gastroenterol"},{"key":"R14-20260108","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"R15-20260108","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1530\/ERC-12-0340","article-title":"Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database.","volume":"20","author":"Ter-Minassian","year":"2013","journal-title":"Endocr Relat Cancer"},{"key":"R16-20260108","doi-asserted-by":"crossref","first-page":"6876","DOI":"10.7150\/jca.32381","article-title":"Treatment patterns and survival among patients with metastatic gastroenteropancreatic neuroendocrine tumours in Sweden \u2013 a population-based register-linkage and medical chart review study.","volume":"10","author":"Les\u00e9n","year":"2019","journal-title":"J Cancer"},{"key":"R17-20260108","doi-asserted-by":"crossref","first-page":"e13249","DOI":"10.1111\/jne.13249","article-title":"European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma.","volume":"35","author":"Sorbye","year":"2023","journal-title":"J Neuroendocrinol"},{"issue":"3_suppl","key":"R18-20260108","doi-asserted-by":"crossref","first-page":"LBA588","DOI":"10.1200\/JCO.2024.42.3_suppl.LBA588","article-title":"[177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: primary analysis of the phase 3 randomized NETTER-2 study.","volume":"42","author":"Simron","year":"2024","journal-title":"JCO"},{"key":"R20-20260108","article-title":"FDA approves lutetium Lu 177 dotatate for pediatric patients 12 years.","year":"2024"},{"key":"R21-20260108","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1111\/cas.15327","article-title":"Neuroendocrine tumor theranostics.","volume":"113","author":"Ichikawa","year":"2022","journal-title":"Cancer Sci"},{"key":"R22-20260108","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1080\/03007995.2022.2065146","article-title":"Real-world comparison of healthcare resource utilization and costs of [177Lu]Lu-DOTA-TATE in patients with progressive neuroendocrine tumors in England: a matched cohort analysis using data from the hospital episode statistics dataset.","volume":"38","author":"Cox","year":"2022","journal-title":"Curr Med Res Opin"},{"key":"R23-20260108","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/MPA.0000000000002101","article-title":"Prospective cohort real-world study on neuroendocrine tumor patient\u2019s quality of life during peptide receptor radionuclide therapy with 177Lu-DOTATATE.","volume":"51","author":"Ramim","year":"2022","journal-title":"Pancreas"},{"key":"R24-20260108","doi-asserted-by":"crossref","first-page":"e644","DOI":"10.1634\/theoncologist.2019-0691","article-title":"Treatment patterns and health resource use among patients with metastatic gastroenteropancreatic neuroendocrine tumors treated at a Tertiary Referral Center.","volume":"25","author":"Jalbert","year":"2020","journal-title":"Oncologist"},{"key":"R25-20260108","doi-asserted-by":"crossref","first-page":"e32044","DOI":"10.1097\/MD.0000000000032044","article-title":"Clinical characteristics of 662 patients with pancreatic neuroendocrine tumors receiving antitumoral therapy.","volume":"101","author":"Loosen","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"R26-20260108","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1007\/s12325-022-02103-7","article-title":"Observational study in a real-world setting of targeted therapy in the systemic treatment of progressive unresectable or metastatic well-differentiated pancreatic neuroendocrine tumors (pNETs) in France: OPALINE study.","volume":"39","author":"Smith","year":"2022","journal-title":"Adv Ther"},{"key":"R27-20260108","doi-asserted-by":"crossref","first-page":"396","DOI":"10.37349\/etat.2023.00141","article-title":"Real world outcomes in patients with neuroendocrine tumor receiving peptide receptor radionucleotide therapy.","volume":"4","author":"Hentzen","year":"2023","journal-title":"Explor Target Antitumor Ther"},{"key":"R28-20260108","doi-asserted-by":"crossref","first-page":"133","DOI":"10.7150\/thno.88619","article-title":"Peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors of unknown primary (CUP-NETs).","volume":"14","author":"Baum","year":"2024","journal-title":"Theranostics"},{"key":"R29-20260108","doi-asserted-by":"crossref","first-page":"232","DOI":"10.14744\/ejmo.2023.48337","article-title":"Assessing the clinical impact of Lutetium-177 DOTATATE peptide receptor radionuclide therapy (PRRT) on metastatic neuroendocrine tumors: a multicenter real-world data from T\u00fcrkiye.","volume":"7","author":"Unal","year":"2023","journal-title":"EJMO"},{"key":"R30-20260108","first-page":"276","article-title":"Neuroendokrine Tumoren des Verdauungstrakts \u2013 Daten des deutschen NET-Registers [Neuroendocrine tumours of the GI tract \u2013 data from the German NET Registry].","volume":"139","author":"Begum","year":"2014","journal-title":"Zentralbl Chir"},{"key":"R31-20260108","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1159\/000242109","article-title":"The German NET-registry: an audit on the diagnosis and therapy of neuroendocrine tumors.","volume":"90","author":"Ploeckinger","year":"2009","journal-title":"Neuroendocrinology"},{"key":"R32-20260108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta15410","article-title":"The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.","volume":"15","author":"Picot","year":"2011","journal-title":"Health Technol Assess"},{"key":"R33-20260108","doi-asserted-by":"crossref","first-page":"17588359211018047","DOI":"10.1177\/17588359211018047","article-title":"Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors.","volume":"13","author":"Das","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"R34-20260108","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00423-020-01868-1","article-title":"Long-term outcome of surgical resection in patients with gastroenteropancreatic neuroendocrine neoplasia: results from a German nation-wide multi-centric registry.","volume":"405","author":"Begum","year":"2020","journal-title":"Langenbecks Arch Surg"},{"key":"R35-20260108","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00428-021-03202-6","article-title":"An analysis of 130 neuroendocrine tumors G3 regarding prevalence, origin, metastasis, and diagnostic features.","volume":"480","author":"Kasajima","year":"2022","journal-title":"Virchows Arch"},{"key":"R36-20260108","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3892\/etm.2021.10613","article-title":"The new WHO classification of gastrointestinal neuroendocrine tumors and immunohistochemical expression of somatostatin receptor 2 and 5.","volume":"22","author":"Popa","year":"2021","journal-title":"Exp Ther Med"},{"key":"R37-20260108","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejca.2022.03.007","article-title":"The European Neuroendocrine Tumour Society registry, a tool to assess the prognosis of neuroendocrine neoplasms.","volume":"168","author":"Borbath","year":"2022","journal-title":"Eur J Cancer"},{"key":"R38-20260108","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s11154-017-9437-9","article-title":"Management of neuroendocrine tumors of unknown primary.","volume":"18","author":"Alexandraki","year":"2017","journal-title":"Rev Endocr Metab Disord"},{"key":"R39-20260108","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.tem.2020.02.010","article-title":"Pancreatic neuroendocrine neoplasms: does sex matter?","volume":"31","author":"Muscogiuri","year":"2020","journal-title":"Trends Endocrinol Metab"},{"key":"R40-20260108","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.3390\/cancers15061863","article-title":"Sex differences in survival from neuroendocrine neoplasia in England 2012\u20132018: a retrospective, population-based study.","volume":"15","author":"White","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R41-20260108","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000505500","article-title":"Influence of gender on therapy and outcome of neuroendocrine tumors of gastroenteropancreatic origin: a single-center analysis.","volume":"36","author":"Mogl","year":"2020","journal-title":"Visc Med"},{"key":"R42-20260108","doi-asserted-by":"crossref","first-page":"7557","DOI":"10.1007\/s00432-023-04711-4","article-title":"Analyses of sex-based clinicopathological differences among patients with gastrointestinal neuroendocrine neoplasms in Europe.","volume":"149","author":"Jann","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"issue":"Suppl 1","key":"R43-20260108","doi-asserted-by":"crossref","first-page":"109","DOI":"10.6061\/clinics\/2012(Sup01)18","article-title":"Diagnostic work-up of gastroenteropancreatic neuroendocrine tumors.","volume":"67","author":"Oberg","year":"2012","journal-title":"Clinics (Sao Paulo)"},{"key":"R44-20260108","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1530\/ERC-15-0119","article-title":"Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms.","volume":"22","author":"Heetfeld","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"R45-20260108","doi-asserted-by":"crossref","first-page":"bvac122","DOI":"10.1210\/jendso\/bvac122","article-title":"Metastatic grade 3 neuroendocrine tumor in multiple endocrine neoplasia type 1 expressing somatostatin receptors.","volume":"6","author":"Graf","year":"2022","journal-title":"J Endocr Soc"},{"key":"R46-20260108","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.adro.2019.03.014","article-title":"Palliative radiation therapy for bone metastases in neuroendocrine neoplasms.","volume":"4","author":"Guan","year":"2019","journal-title":"Adv Radiat Oncol"},{"key":"R47-20260108","doi-asserted-by":"crossref","first-page":"2042018818804698","DOI":"10.1177\/2042018818804698","article-title":"Current best practice in the management of neuroendocrine tumors.","volume":"10","author":"Tsoli","year":"2018","journal-title":"Ther Adv Endocrinol Metab"},{"key":"R48-20260108","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.3390\/cancers15112975","article-title":"Peptide Receptor Radionuclide Therapy (PRRT): innovations and improvements.","volume":"15","author":"Merola","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R49-20260108","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1097\/RLU.0000000000003170","article-title":"Peptide receptor radionuclide therapy as first-line systemic treatment in advanced inoperable\/metastatic neuroendocrine tumors.","volume":"45","author":"Satapathy","year":"2020","journal-title":"Clin Nucl Med"},{"key":"R50-20260108","doi-asserted-by":"crossref","first-page":"5792","DOI":"10.3390\/cancers14235792","article-title":"A clinical guide to peptide receptor radionuclide therapy with 177Lu-DOTATATE in neuroendocrine tumor patients.","volume":"14","author":"Becx","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R51-20260108","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1530\/ERC-16-0524","article-title":"Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate.","volume":"24","author":"Brabander","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"R52-20260108","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1212\/01.WNL.0000133398.11870.9A","article-title":"Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.","volume":"63","author":"de Wit","year":"2004","journal-title":"Neurology"},{"key":"R53-20260108","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000475526","article-title":"ENETS consensus guidelines for the standards of care in neuroendocrine neoplasia: peptide receptor radionuclide therapy with radiolabeled somatostatin analogues.","volume":"105","author":"Hicks","year":"2017","journal-title":"Neuroendocrinology"},{"key":"R54-20260108","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.3390\/cancers15194836","article-title":"Monitoring and surveillance of patients with gastroenteropancreatic neuroendocrine tumors undergoing radioligand therapy.","volume":"15","author":"Halfdanarson","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R55-20260108","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1200\/JCO.2007.12.1368","article-title":"End points in advanced colon cancer clinical trials: a review and proposal.","volume":"25","author":"Allegra","year":"2007","journal-title":"J Clin Oncol"},{"key":"R56-20260108","doi-asserted-by":"crossref","first-page":"e000399","DOI":"10.1136\/esmoopen-2018-000399","article-title":"Evaluation of time to failure of strategy as an alternative surrogate endpoint in patients with lung cancer with EGFR mutations.","volume":"3","author":"Shinno","year":"2018","journal-title":"ESMO Open"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041853","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T21:00:14Z","timestamp":1767906014000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":55,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000041853","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,14]]}}}